From a cancer drug fund to value based pricing of drugs: Such pricing may be hard to implement and may not add value

Autor:	Duerden, Martin
Zdroj:	BMJ: British Medical Journal, 2010 Aug . 341(7770), 412-413.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/20766182 Zobrazit plný text záznamu